Sanofi nabs new use for Taxotere

Sanofi-Aventis won the FDA's nod for a new use for its cancer drug Taxotere. Now it can be marketed for use in head and neck cancers. Clinical trials had shown that Taxotere plus standard chemo boosted survival rate by more than three years. The drug has already been approved in the U.S. and Europe for breast, lung, prostate, and gastric cancers.

- see Sanofi's release

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.